Your browser doesn't support javascript.
loading
A novel long-acting formulation of oral buprenorphine/naloxone produces prolonged decreases in fentanyl self-administration by rhesus monkeys.
Foltin, Richard W; Zale, Stephen; Sykes, Kristine A; Nagaraj, Nayana; Scranton, Richard E; Comer, Sandra D.
Afiliação
  • Foltin RW; Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA. Electronic address: rwf2@cumc.columbia.
  • Zale S; Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02472, USA.
  • Sykes KA; Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02472, USA.
  • Nagaraj N; Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02472, USA.
  • Scranton RE; Lyndra Therapeutics, Inc., 65 Grove St, Watertown, MA 02472, USA.
  • Comer SD; Division on Substance Use Disorders, New York State Psychiatric Institute and Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons and Columbia University Irving Medical Center, 1051 Riverside Drive, New York, NY 10032, USA.
Drug Alcohol Depend ; 239: 109599, 2022 10 01.
Article em En | MEDLINE | ID: mdl-35963210
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Idioma: En Ano de publicação: 2022 Tipo de documento: Article